Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|38|10|1236-1247

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.38, Iss.10, 2013-11, pp. : 1236-1247

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tuberculous peritonitis after treatment with adalimumab

By Antolin Jose   Azahara Marcos   Hernandez Clara   Blanco Margarita   Mao Laura   Ciguenza Ramon  

Scandinavian Journal of Infectious Diseases, Vol. 40, Iss. 8, 2008-01 ,pp. : 677-678

Informa Healthcare

Access to resources Recommend Favorite

A practical, evidence-based guide to the use of adalimumab in Crohn’s disease

By Rubin David T.   Panaccione Remo   Chao Jingdong   Robinson Anne M.  

Current Medical Research and Opinion, Vol. 27, Iss. 9, 2011-09 ,pp. : 1803-1813

Informa Healthcare

Access to resources Recommend Favorite

Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease – authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 2, 2015-07 ,pp. : 241-241

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 2, 2015-07 ,pp. : 240-240

John Wiley & Sons Inc

Access to resources Recommend Favorite

Increased Probability of Remaining in Remission from Panic Disorder with Agoraphobia after Drug Treatment in Patients Who Received Concurrent Cognitive-Behavioural Therapy: A Follow-Up Study

By  

Psychotherapy and Psychosomatics, Vol. 72, Iss. 1, 2002-12 ,pp. : 34-42

Karger

Access to resources Recommend Favorite